Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
INmune Bio is a clinical-stage immunotherapy company developing treatments for cancer and Alzheimer's disease, with lead programs including XPro1595 (TNF inhibitor for treatment-resistant depression and Alzheimer's) and INKmune (primed NK cell therapy for ovarian cancer and other solid tumors). The company has no commercial revenue and is entirely dependent on clinical trial execution, regulatory milestones, and capital markets access for survival. Stock performance is driven by clinical data readouts, FDA interactions, and cash runway visibility.
INmune Bio operates a dual-platform model targeting distinct therapeutic areas. XPro1595 is a dominant-negative TNF inhibitor designed to selectively neutralize soluble TNF while preserving transmembrane TNF signaling, positioning it for neuroinflammatory conditions including treatment-resistant depression and Alzheimer's disease. INKmune is an allogeneic NK cell priming platform that activates natural killer cells ex vivo for enhanced tumor targeting in solid tumors. The company's value creation depends on demonstrating clinical proof-of-concept, achieving regulatory milestones (IND approvals, Phase 2/3 advancement), and ultimately partnering assets or commercializing independently. With 100% gross margin reflecting zero revenue and massive operating losses, the business model is pure R&D capital consumption until pivotal trial success enables partnership economics or product launch.
XPro1595 clinical trial data releases for treatment-resistant depression and Alzheimer's disease (primary/secondary endpoints, safety profile)
INKmune Phase 2 data in ovarian cancer and other solid tumor indications (response rates, progression-free survival)
FDA regulatory interactions including IND clearances, Fast Track designations, or clinical hold resolutions
Capital raises and cash runway updates - equity offerings, debt facilities, or strategic partnerships that extend operational viability
Competitive landscape shifts in TNF inhibition or NK cell therapy spaces affecting differentiation thesis
Clinical trial failure risk - XPro1595 or INKmune could fail to demonstrate efficacy/safety in ongoing trials, rendering platforms worthless and triggering potential wind-down scenarios
Regulatory pathway uncertainty - FDA may require larger/longer trials than anticipated, particularly for novel mechanisms like selective TNF inhibition in CNS indications, extending timelines and capital requirements beyond current runway
Capital markets dependence - company requires continuous access to equity financing given negative cash flow; adverse market conditions or loss of investor confidence could prevent necessary capital raises, forcing asset sales or bankruptcy
TNF inhibitor competition from established biologics (Humira biosimilars, Enbrel) and emerging selective inhibitors that could demonstrate superior efficacy or safety profiles in overlapping indications
NK cell therapy competition from better-capitalized players (Fate Therapeutics, Nkarta) with iPSC-derived or CAR-NK platforms that may achieve earlier commercialization or demonstrate superior tumor targeting
Alzheimer's landscape shift following recent approvals of anti-amyloid antibodies (Leqembi, Kisunla) potentially reducing interest in alternative neuroinflammatory mechanisms
Cash burn sustainability - with -$0.0B operating cash flow (estimated $15-25M annual burn based on typical Phase 2 biotech), current cash may only support 12-18 months of operations, requiring near-term dilutive financing
Equity dilution risk - 85.3% one-year decline and minimal market cap suggest future raises will occur at depressed valuations, causing severe shareholder dilution and potential reverse split necessity to maintain listing compliance
low - Clinical-stage biotechs are largely insulated from GDP fluctuations as trial timelines and regulatory processes operate independently of economic cycles. However, severe recessions can impact capital availability for financing and reduce M&A/partnership activity from larger pharma acquirers. Patient enrollment may experience modest delays during economic stress but core business operations are non-cyclical.
Rising interest rates create significant headwinds through multiple channels: (1) Higher discount rates compress NPV of distant future cash flows, disproportionately impacting pre-revenue biotechs with 5-10 year commercialization timelines; (2) Risk-free rate competition makes speculative equity less attractive to investors; (3) Tighter financial conditions reduce availability and increase cost of capital for dilutive equity raises that fund operations. The 4.17x current ratio provides near-term liquidity buffer but doesn't eliminate refinancing risk. Rate cuts would be modestly positive by improving risk appetite and valuation multiples.
Minimal direct credit exposure given negligible debt (0.04 D/E ratio) and no commercial operations requiring trade credit. However, credit market conditions indirectly affect biotech financing environment - widening high-yield spreads signal risk-off sentiment that reduces investor appetite for speculative equities and increases equity dilution required for capital raises. Tight credit conditions also constrain potential pharma partners' M&A capacity.
growth/speculative - Attracts high-risk-tolerance investors seeking asymmetric returns from clinical-stage binary events. Typical shareholders include specialized biotech hedge funds, retail speculators, and venture-style investors willing to accept total loss probability in exchange for potential 5-10x returns on successful trial readouts. The -85.3% one-year return and minimal institutional ownership suggest current holder base is predominantly speculative retail with some distressed/event-driven funds. Not suitable for value or income investors given no earnings, dividends, or tangible asset backing.
high - Clinical-stage biotechs exhibit extreme volatility around binary catalysts (trial data, FDA decisions). Stock likely trades with beta >2.0 relative to broader market and experiences 20-50% single-day moves on material news. The -46.6% six-month decline demonstrates sustained downward pressure typical of pre-revenue biotechs during risk-off periods. Illiquidity from small market cap amplifies volatility as modest order flow creates outsized price impacts.
